Stability indicating assay method for simultaneous estimation of nebivolol and valsartan in pharmaceutical dosage form by RP-HPLC
Journal: Asian Journal of Green Chemistry (Vol.2, No. 3)Publication Date: 2018-07-01
Authors : Amit Vyas; Grishma Nathwani; Ajay Patel; Ashok Patel; Nilesh Patel; Nirav Makvana;
Page : 227-245
Keywords : Nebivolol; valsartan; RP-HPLC; Stability indicating; Validation;
Abstract
A simple, rapid, precise, and accurate isocratic reversed-phase stability indicating HPLC method was developed and validated for simultaneous determination of the nebivolol and valsartan in the tablet dosage form. The effective chromatographic separation was achieved by a YMC pack pro octadecyl silane (150×4.6 mm, 3 µm) column using a mobile phase composed of methanol: acetonitrile: 0.05 M potassium dihydrogen phosphate buffer (Ph=3.0 with 10% ortho phosphoric acid after addition of 0.2% triethylamine) (30:30:40, v/v/v) at a flow rate of 1 mL/min and UV detection at 282 nm. Drugs were subjected to the acid, base, oxidation, heat, and photolysis to apply the stress. Linearity ranges were 5–30 µg/mL (r2= 0.9989) for nebivolol and 80-480 µg/mL (r2=0.9991) for valsartan. Limit of detection was 0.38 µg/mL and 1.08 µg/mL for nebivolol and valsartan, respectively. The limit of quantification for the nebivolol and valsartan was 1.15 µg/mL and 3.27 µg/mL, respectively.
Other Latest Articles
- Cloud Accounting As a New Business Model and Its Influence on Accounting Process
- Interstitial Cystitis Client, CC: Treated With STSH over Skype: From Irvine, CA to Pine Brook, New Jersey
- Synthesis of N-formyl morpholine as green solvent in the synthesis of organic compounds
- Propargylation of indole under a new dual-site phase-transfer catalyst: A kinetic study
- Modification of montmorillonite clay with 2-mercaptobenzimidazole and investigation of their antimicrobial properties
Last modified: 2018-06-05 19:54:51